Salk Institute

Technologies Available for Licensing

Increased Reprogramming for Generating Pluripotent Stem Cells

Inventors: Teruhisa Kawamura, Jotaro Suzuki, Geoffrey M. Wahl & Juan Carlos Izpisua Belmonte
Potential Uses: Drug Discovery, Gene Expression, Research Tool, Stem Cells

Induced pluripotent stem (iPS) cell generation using two factors and p53 inactivation

The p53 pathway limits reprogramming efficiency. Reprogramming factors/stimuli produce a "reprogramming stress" in somatic cells that activates the p53 pathway. This stress is caused by proto-oncogene over-expression. Eliminating or inhibiting p53 significantly increases reprogramming.

Reprogramming somatic cells to induced pluripotent stem (iPS) cells has been accomplished by expressing pluripotency factors and oncogenes, but 1) the low frequency and 2) the tendency to induce malignant transformation compromise the clinical utility of this powerful approach.

We have developed a method that increases the frequency of reprogramming and reduces the possibility of malignancy in the transformed cells. To do this, we reduce signaling to p53 (either by expressing a mutated version of one of its negative regulators, or by deleting or knocking down p53 or its target gene, p21) or we antagonize reprogramming-induced apoptosis. Quite notably, decreasing p53 protein levels enabled fibroblasts to give rise to iPS cells capable of generating germline-transmitting chimaeric mice using only Oct4 and Sox2. Furthermore, silencing of p53 significantly increased the reprogramming efficiency of human somatic cells. These results provide insights into reprogramming mechanisms and suggest new routes to more efficient reprogramming while minimizing the use of oncogenes.

Salk No: S09011
Patent Status: U.S. Patent Application Filed March 2009
Publications: Teruhisa Kawamura, Jotaro Suzuki, Yunyuan V. Wang, Sergio Menendez, Laura Batlle Morera, Angel Raya, Geoffrey M. Wahl & Juan Carlos Izpisua Belmonte. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature: On line Aug 9, 2009 Supplement
Press Release: Tumor suppressor pulls double shift as reprogramming watchdog
License Terms: Exclusive, Partially Exclusive, Nonexclusive license negotiable
Contact: Michelle Booden, Ph.D., Director of Licensing, 858.453.4100 x1612, mbooden@salk.edu

Get Involved

Sign up for our email newsletter

Fill out my online form.
Contact
Salk Institute for Biological Studies
Street: 10010 N Torrey Pines Rd
City: La Jolla, CA 92037
Email: webrequest@salk.edu
Phone: 858.453.4100
Charity Navigator Rating
  • Salk Twitter
  • Salk LinkedIn
  • Salk Facebook
  • Salk Instagram
  • Salk Google+
  • Salk YouTube
  • Salk RSS Feed
© Copyright 2014 Salk Institute for Biological Studies | Privacy Policy About Scientists & Research News & Media Events Support